NASA Tests On-Demand IV Fluid Production System for Deep Space Missions
Similar Articles
NASA Completes Key Testing Phase for Moon Mission Power System
NASA and SpaceX Target Mid-May Launch for Space Station Resupply Mission
NASA Awards $6.9 Million Contract to Advance Lunar Resource Extraction
Astronauts Process Genetic Samples for Cancer Treatment Research on Space Station
NASA Tests New 'Dry' Cryogenic Rig to Simulate Harsh Lunar Nights
NASA has installed a miniaturized system on the International Space Station (ISS) that can filter drinking water to produce medical-grade intravenous (IV) fluid. This technology, developed to support long-duration missions, is scheduled for operational demonstrations in 2026. The system could provide a critical medical resource for future crewed missions to the Moon and Mars.
Facts First
- IVGEN Mini system installed on ISS to produce IV fluid from station drinking water.
- System can treat up to 30% of inflight medical conditions, including dehydration and burns.
- On-demand production addresses limited shelf life of pre-packed IV fluids for multi-year missions.
- Demonstrations planned in 2026 will generate 10 liters of fluid for safety analysis on Earth.
- Technology is managed by NASA’s Mars Campaign Office as part of Moon and Mars exploration plans.
What Happened
The IntraVenous Fluid GENeration Miniaturized (IVGEN Mini) system was installed in a replica of the International Space Station’s Life Sciences Glovebox at NASA’s Marshall Space Flight Center in November 2025. It flew to the ISS on April 11, 2026, aboard a Northrop Grumman Commercial Resupply Services mission. The system is scheduled to produce IV fluid during demonstrations in the spring and fall of 2026 to verify its design works in space. Tentative operations are planned for May 2026, during which the ISS crew will generate 10 liters of fluid over two days.
Why this Matters to You
For astronauts on future deep-space missions, access to medical supplies is a critical safety concern. IV fluid can treat up to 30% of medical conditions in flight, but the current pre-packed supply has a limited shelf life of 16 months. This new system could provide a reliable, on-demand source of sterile IV fluid, enhancing crew health and mission resilience. The technology's success may also lead to more advanced, compact medical systems for exploration.
What's Next
The 10 liters of fluid generated during the ISS demonstrations will be returned to Earth for analysis to ensure it meets safety requirements. None of this fluid will be administered to the crew. The IVGEN Mini team is planning a next phase involving shelf-life testing of the produced IV fluid. Successful verification of the system could make it a standard component for future crewed missions to the Moon and Mars.